Lonza provided several updates on its plans for Moderna's experimental COVID-19 vaccine, one being it is speeding completion of a commercial production line at its New Hampshire facility to earlier than December and another commercial line in Switzerland before the end of the year, to enable the company to manufacture ingredients for an estimated 600 million to 1 billion doses of the vaccine annually. Moderna enlisted the help of Lonza in May through a 10-year manufacturing contract for its COVID-19 vaccine candidate.
Lonza speeds production deadlines for Moderna COVID-19 vaccine
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.